Related Experiment Videos
Serum SCC-Ag in head and neck squamous cell carcinoma
F Palermo1, A Carniato, A Fede
1Nuclear Medicine Service, Treviso Hospital, Italy.
The International Journal of Biological Markers
|July 1, 1990
Summary
This study found that elevated serum levels of squamous cell carcinoma antigen (SCC-Ag) are common in head and neck cancer patients. Combining SCC-Ag, CEA, and TPA tests improves diagnostic sensitivity for these tumors.
Area of Science:
- Oncology
- Biochemistry
Background:
- Head and neck neoplasia presents a significant health challenge.
- Accurate diagnostic markers are crucial for early detection and effective management of head and neck cancers.
Purpose of the Study:
- To evaluate the diagnostic utility of serum tumor markers: squamous cell carcinoma antigen (SCC-Ag), carcinoembryonic antigen (CEA), and tissue polypeptide antigen (TPA).
- To assess the combined efficacy of these markers in patients with head and neck neoplasia.
Main Methods:
- Serum levels of SCC-Ag, CEA, and TPA were measured in 69 patients with head and neck neoplasia and 31 healthy controls.
- A radioimmunometric method (double antibody) was employed for quantification.
Main Results:
- SCC-Ag concentrations were significantly elevated in 43.4% of cancer patients compared to controls, with a specificity of 96.7%.
- The diagnostic value of markers varied with the disease's evolutionary phase.
- Combined evaluation of SCC-Ag, TPA, and CEA increased sensitivity to 71.0%.
Conclusions:
- SCC-Ag shows promise as a biomarker for head and neck neoplasia.
- The combined use of SCC-Ag, TPA, and CEA offers improved sensitivity for diagnosing head and neck tumors.
- These markers are valuable tools for monitoring tumoral pathology in this region.